7 June 2024
To: Kewpie Corporation
Mr Mitsuru Takamiya, President and Representative Director
From:
Consumers Union of Japan (NPO)
No! GMO Campaign
Questionnaire on genome-edited eggs (allergen-reduced eggs)
Thank you for responding to the questionnaire we sent in January 2024 in response to media reports that your company has developed a low-allergen egg using genome editing technology in collaboration with Hiroshima University and is conducting clinical trials at the National Hospital Organisation Sagamihara Hospital. We would like to ask you a few questions again, as there were some points that were unclear in your response and there were also reports that your company has started a clinical trial. Please reply in writing by 21 June. Your answers will be published on our organisation’s website.
Q1: In your previous answer, you stated that you have completed safety checks, but what specific safety checks have you carried out?
Q2: In your opinion, how about even minor changes in clinical trials? They should not be overlooked as signs of serious health effects. What kind of observations would you make, and what kind of abnormalities would you consider stopping the trial?
Q3: How will the progress and results of the clinical trials be made public?